Annual report
4978.TEDINET S100TRSE
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥409m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | −¥356m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥40m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥120m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥507m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥789m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥892m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥29m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥304m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥31m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥305m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥575m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥813m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.0bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥31m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | −¥305m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥9.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥8.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥8.1bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥741m | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥781m | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥5.4bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.1bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.9bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.6bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥11m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥141m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥246m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥649m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥690m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥404m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥544m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥483m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥4m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥7m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-0.37 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.62 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.57 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.38 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.27 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥93.41 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥89.01 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥88.11 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥75.17 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥84.76 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 91.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 96 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 92 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 98 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 106 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 113 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥941m | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥1.6bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥606m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥429m | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥387m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | −¥337m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | −¥62m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥112m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥382m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥559m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥564m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥203m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥296m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | −¥205m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥297m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥541m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥997m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥905m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.8bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥8.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥8.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥408m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥522m | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥8.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥7.5bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥5.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-2.4 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.52 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.13 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.96 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.71 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥94.05 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥92.42 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.73 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥79.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.69 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 95.3% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.1% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 89,013,591 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,141,191 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 82,270,891 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 71,667,391 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 71,406,891 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 26 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 28 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 31 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥14m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥8.1bn |
| Reconciling Itemsreconciling | segment ordinary income | 2023-04-01 → 2024-03-31 | −¥626m |
| Medical Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥107m |
| Medical Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥14m |
| Medical Businessreportable segment | employees | at 2024-03-31 | 6 pure |
| Medical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥347m |
| Medical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥347m |
| Medical Businessreportable segment | segment assets | at 2024-03-31 | ¥227m |
| Medical Businessreportable segment | segment ordinary income | 2023-04-01 → 2024-03-31 | ¥221m |
| Research Support Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥83m |
| Research Support Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥7m |
| Research Support Businessreportable segment | employees | at 2024-03-31 | 67 pure |
| Research Support Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Research Support Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Research Support Businessreportable segment | segment assets | at 2024-03-31 | ¥685m |
| Research Support Businessreportable segment | segment ordinary income | 2023-04-01 → 2024-03-31 | ¥446m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥190m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥21m |
| —segment total | employees | at 2024-03-31 | 73 pure |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| —segment total | segment assets | at 2024-03-31 | ¥911m |
| —segment total | segment ordinary income | 2023-04-01 → 2024-03-31 | ¥666m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥3m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥11m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥7.5bn |
| Reconciling Itemsreconciling | segment ordinary income | 2022-04-01 → 2023-03-31 | −¥543m |
| Medical Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥121m |
| Medical Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥30m |
| Medical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥936m |
| Medical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥936m |
| Medical Businessreportable segment | segment assets | at 2023-03-31 | ¥133m |
| Medical Businessreportable segment | segment ordinary income | 2022-04-01 → 2023-03-31 | ¥56m |
| Research Support Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥37m |
| Research Support Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5m |
| Research Support Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | segment assets | at 2023-03-31 | ¥683m |
| Research Support Businessreportable segment | segment ordinary income | 2022-04-01 → 2023-03-31 | ¥367m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥158m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥35m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| —segment total | segment assets | at 2023-03-31 | ¥815m |
| —segment total | segment ordinary income | 2022-04-01 → 2023-03-31 | ¥423m |
| Medical Businessreportable segment | employees | at 2024-03-31 | 6 pure |
| Research Support Businessreportable segment | employees | at 2024-03-31 | 13 pure |
| —segment total | employees | at 2024-03-31 | 19 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,440
| Item | Context | Value | Unit |
|---|---|---|---|
| Deferred tax liabilities | CurrentYearInstant_NonConsolidatedMember | 53660000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant_NonConsolidatedMember | 7754000 | JPY |
| Asset retirement obligations ncl | CurrentYearInstant_NonConsolidatedMember | 8969000 | JPY |
| Noncurrent liabilities | Prior1YearInstant_NonConsolidatedMember | 30962000 | JPY |
| Noncurrent liabilities | CurrentYearInstant_NonConsolidatedMember | 62630000 | JPY |
| Liabilities | Prior1YearInstant_NonConsolidatedMember | 521749000 | JPY |
| Liabilities | CurrentYearInstant_NonConsolidatedMember | 407879000 | JPY |
| Capital stock | Prior1YearInstant_NonConsolidatedMember | 2023770000 | JPY |
| Capital stock | CurrentYearInstant_NonConsolidatedMember | 2322198000 | JPY |
| Legal capital surplus | Prior1YearInstant_NonConsolidatedMember | 6111751000 | JPY |
| Legal capital surplus | CurrentYearInstant_NonConsolidatedMember | 6410178000 | JPY |
| Capital surplus | Prior1YearInstant_NonConsolidatedMember | 6111751000 | JPY |
| Capital surplus | CurrentYearInstant_NonConsolidatedMember | 6410178000 | JPY |
| Retained earnings brought forward | Prior1YearInstant_NonConsolidatedMember | -296701000 | JPY |
| Retained earnings brought forward | CurrentYearInstant_NonConsolidatedMember | -501924000 | JPY |
| Retained earnings | Prior1YearInstant_NonConsolidatedMember | -296701000 | JPY |
| Retained earnings | CurrentYearInstant_NonConsolidatedMember | -501924000 | JPY |
| Treasury stock | Prior1YearInstant_NonConsolidatedMember | -916000 | JPY |
| Treasury stock | CurrentYearInstant_NonConsolidatedMember | -916000 | JPY |
| Shareholders equity | Prior1YearInstant_NonConsolidatedMember | 7837903000 | JPY |
| Shareholders equity | CurrentYearInstant_NonConsolidatedMember | 8229536000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant_NonConsolidatedMember | 27643000 | JPY |
| Valuation difference on available for sale securities | CurrentYearInstant_NonConsolidatedMember | 135651000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant_NonConsolidatedMember | 27643000 | JPY |
| Valuation and translation adjustments | CurrentYearInstant_NonConsolidatedMember | 135651000 | JPY |
| Subscription rights to shares | Prior1YearInstant_NonConsolidatedMember | － | JPY |
| Subscription rights to shares | CurrentYearInstant_NonConsolidatedMember | 3419000 | JPY |
| Net assets | Prior1YearInstant_NonConsolidatedMember | 7865546000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember | 8368607000 | JPY |
| Liabilities and net assets | Prior1YearInstant_NonConsolidatedMember | 8387295000 | JPY |
| Liabilities and net assets | CurrentYearInstant_NonConsolidatedMember | 8776486000 | JPY |
| Net sales of finished goods rev oa | Prior1YearDuration_NonConsolidatedMember | 552424000 | JPY |
| Net sales of finished goods rev oa | CurrentYearDuration_NonConsolidatedMember | 551225000 | JPY |
| Service revenue rev oa | Prior1YearDuration_NonConsolidatedMember | 998304000 | JPY |
| Service revenue rev oa | CurrentYearDuration_NonConsolidatedMember | 390255000 | JPY |
| Net sales | Prior1YearDuration_NonConsolidatedMember | 1550728000 | JPY |
| Net sales | CurrentYearDuration_NonConsolidatedMember | 941480000 | JPY |
| Cost of finished goods sold | Prior1YearDuration_NonConsolidatedMember | 420415000 | JPY |
| Cost of finished goods sold | CurrentYearDuration_NonConsolidatedMember | 396170000 | JPY |
| Cost of service operations cos | Prior1YearDuration_NonConsolidatedMember | 658922000 | JPY |
| Cost of service operations cos | CurrentYearDuration_NonConsolidatedMember | 177169000 | JPY |
| Cost of sales | Prior1YearDuration_NonConsolidatedMember | 1079337000 | JPY |
| Cost of sales | CurrentYearDuration_NonConsolidatedMember | 573339000 | JPY |
| Gross profit | Prior1YearDuration_NonConsolidatedMember | 471391000 | JPY |
| Gross profit | CurrentYearDuration_NonConsolidatedMember | 368141000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 339474000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 230595000 | JPY |
| Other selling general and administrative expenses sga | Prior1YearDuration_NonConsolidatedMember | 469392000 | JPY |
| Other selling general and administrative expenses sga | CurrentYearDuration_NonConsolidatedMember | 524939000 | JPY |
| Selling general and administrative expenses | Prior1YearDuration_NonConsolidatedMember | 808866000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |